Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Modern Pathology

• Publication date

  2018-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/modpathol.2017.129PMID 28984296
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.

  2017cited by this paper
• Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

  2016cited by this paper
• The Genomic Landscape of Male Breast Cancers

  2016cited by this paper
• Abstract P3-07-15: Prosigna® subtype correlation is a strong predictor of response to neoadjuvant chemotherapy (NAC) in early breast cancer (EBC) study

  2016cited by this paper
• Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.

  2016cited by this paper
• Prognostic significance of tumor subtypes in male breast cancer: a population-based study

  2015cited by this paper
• Development and verification of the PAM50-based Prosigna breast cancer gene signature assay

  2015cited by this paper
• Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

  2014cited by this paper
• Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.

  2014cited by this paper
• The prognostic significance of molecular subtype for male breast cancer: a 10-year retrospective study.

  2013cited by this paper
• Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

  2013cited by this paper
• Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact

  2013cited by this paper
• Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

  2013cited by this paper
• Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine.

  2013cited by this paper
• Comprehensive molecular portraits of human breast tumors

  2012cited by this paper
• Male Breast Cancer: Immunohistochemical Subtypes and Clinical Outcome Characterization

  2012cited by this paper
• A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences

  2012cited by this paper
• Molecular subtyping of male breast cancer by immunohistochemistry

  2012cited by this paper
• Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker

  2012cited by this paper
• Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer

  2011cited by this paper
• High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer

  2011cited by this paper
• Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers.

  2011cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010cited by this paper
• Multidisciplinary meeting on male breast cancer: summary and research recommendations.

  2010cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).

  2010cited by this paper
• Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.

  2010cited by this paper
• Immunohistochemical characterization of subtypes of male breast carcinoma

  2009cited by this paper
• Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

  2009cited by this paper
• Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

  2008cited by this paper
• A review of the diagnosis and management of male breast cancer.

  2005cited by this paper
• Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma

  2004cited by this paper
• Repeated observation of breast tumor subtypes in independent gene expression data sets

  2003cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper

• The Oncotype DX® 21-gene recurrence score and clinical outcomes in hormone receptor-positive, HER2-negative male breast cancer: a scoping review.

  2025cites this paper
• Ki67 Expression and Its Association With Clinicopathological Factors and Intrinsic Subtypes of Male Breast Cancer in Uganda: A Cross-sectional Study

  2025cites this paper
• Treatments of Interest in Male Breast Cancer: An Umbrella Review

  2025cites this paper
• HER2 expression and pathway status in male breast cancer patients: results of an integrated analysis among 6,150 patients

  2025cites this paper
• Clinicopathological Features, Treatment Patterns, and Survival Outcomes in Male Breast Cancer: A Multicenter Retrospective Analysis from the Czech Republic (2007–2017)

  2024cites this paper
• Genomic profiling and comparative analysis of male versus female metastatic breast cancer across subtypes

  2024cites this paper
• Treatment and Prognosis of Male Breast Cancer: A Multicentric, Retrospective Study Over 11 Years in the Czech Republic

  2024cites this paper
• Sexual Dimorphism of Skeletal Muscle in a Mouse Model of Breast Cancer: A Functional and Molecular Analysis

  2023cites this paper
• Treatment utilization and effectiveness of neoadjuvant chemotherapy comparing men and women diagnosed with breast cancer: a Swedish retrospective cohort study

  2023cites this paper
• Survival in male breast cancer over the past three decades.

  2022cites this paper
• Relevance of the 21-gene expression assay in male breast cancer: A systematic review and meta-analysis

  2022cites this paper
• The potential effects and mechanisms of breast inflammatory lesions on the occurrence and development of breast cancer

  2022cites this paper
• The Prevalence and Death Risk of Male Breast Cancer: A Study Based on the Surveillance, Epidemiology, and End Results Database

  2022cites this paper
• Efficacy of neoadjuvant chemotherapy in male breast cancer compared with female breast cancer

  2022cites this paper
• Evaluation of multiple transcriptomic gene risk signatures in male breast cancer

  2021cites this paper
• Mammakarzinom beim Mann

  2021cites this paper
• Evaluation of multiple transcriptomic gene risk signatures in male breast cancer

  2021cites this paper
• Genetic Testing

  2021cites this paper
• Tumor subtypes and survival in male breast cancer

  2021cites this paper
• The Significance Of Hormone Receptors In Male Breast Cancer

  2020cites this paper
• Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis In Patients With Breast Cancer

  2020cites this paper
• Subtyping of male breast cancer by PAM50 and immunohistochemistry: a pilot study of a consecutive Danish cohort

  2020influential citation
• Male breast cancer: clinicopathological characterization of a National Danish cohort 1980–2009

  2020cites this paper
• Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Effective : February 1 , 2019

  2019cites this paper
• Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications

  2019cites this paper
• Overall Survival of Men and Women With Breast Cancer According to Tumor Subtype: A Population-based Study

  2019cites this paper
• Long-Term Follow-Up of Patients with Male Breast Cancer , Single-Center Experience

  2019cites this paper
• Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis In Patients With Breast Cancer Effective : July 1 , 2018

  2018cites this paper
• Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis In Patients With Breast Cancer

  2018cites this paper
• Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Effective : November 1 , 2018

  2018cites this paper
• Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Effective : January 1 , 2019

  2018cites this paper
• Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis In Patients With Breast Cancer Effective : March 1 , 2018

  2018cites this paper
• Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Effective : August 1 , 2018

  2018cites this paper